Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human GNX1021 in unresectable or metastatic gastrointestinal cancers
jRCT2031260141Phase 1Recruiting
- Sponsor
- GlycoNex
- Start
- Jul 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 1, open-label trial of GNX1021 in gastrointestinal cancer, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more (3 arms), sponsored by GlycoNex. Primary endpoint: Safety and adverse events. Started Jul 2026; status: recruiting.
02
Drugs
GNX1021
03
Conditions
gastrointestinal cancergastric adenocarcinomagastroesophageal junction adenocarcinomapancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on jRCT2031260141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260141.